Current challenges in personalizing warfarin therapy

Expert Review of Clinical Pharmacology

Volumn 4, Issue 3, 2011, Pages 349-362

  McMillin, Gwendolyn A ^a   Vazquez, Sara R ^b   Pendleton, Robert C ^c  

^a ARUP LABORATORIES   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

patient self management; patient self testing; pharmacogenetics; vitamin K; vitamin K antagonist; warfarin

Indexed keywords

7 HYDROXYWARFARIN; AMIODARONE; ANTIVITAMIN K; CYTOCHROME P450 2C9; CYTOCHROME P450 4A; CYTOCHROME P450 4AF2; DRUG METABOLITE; OXIDOREDUCTASE; PHENPROCOUMON; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE 1; VITAMIN K GROUP; WARFARIN;

ALGORITHM; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; GENE FREQUENCY; GENE TARGETING; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LOW DRUG DOSE; MAINTENANCE THERAPY; MODEL; PATIENT MONITORING; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRESCRIPTION; RACE DIFFERENCE; REVIEW; SELF MONITORING; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; GENETIC VARIATION; HUMANS; INDIVIDUALIZED MEDICINE; INTERNATIONAL NORMALIZED RATIO; VITAMIN K; WARFARIN;

EID: 79955964742     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.15     Document Type: Review

References (80)

1. Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br. J. Haematol. 141(6), 757-763 (2008). (Pubitemid 351724858)
2. Francis CW. Warfarin: an historical perspective. Hematology Am. Soc. Hematol. Educ. Program 251 (2008).
3. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch. Intern. Med. 167(13), 1414-1419 (2007). (Pubitemid 47052441)
4. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest 133(6 Suppl.), 160S-198S (2008). (Pubitemid 351892967)
5. Wessler S, Gitel SN. Warfarin. From bedside to bench. N. Engl. J. Med. 311(10), 645-652 (1984). (Pubitemid 14027330)
6. Hull R, Delmore T, Genton E et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N. Engl. J. Med. 301(16), 855-858 (1979). (Pubitemid 10165871)
7. Kirkwood TB. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb. Haemost. 49(3), 238-244 (1983). (Pubitemid 13060101)
8. Hull R, Hirsh J, Jay R et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N. Engl. J. Med. 307(27), 1676-1681 (1982). (Pubitemid 13206049)
9. Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 349(11), 1019-1026 (2003). (Pubitemid 37087616)
10. Masaki N, Suzuki M, Matsumura A, Maruyama Y, Hashimoto Y. Quality of warfarin control affects the incidence of stroke in elderly patients with atrial fibrillation. Intern. Med. 49(16), 1711-1716 (2010).
11. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb. Res. 124(1), 37-41 (2009).
12. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J. Manag. Care Pharm. 15(3), 244-252 (2009).
13. Brockmoller J, Tzvetkov MV. Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur. J. Clin. Pharmacol. 64(2), 133-157 (2008).
14. Holmes MV, Shah T, Vickery C, Smeeth L, Hingorani AD, Casas JP. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One 4(12), e7960 (2009).
15. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N. Engl. J. Med. 358(6), 637-639 (2008). (Pubitemid 351214293)
16. Coumadin® (warfarin sodium), package insert. Bristol Myers Squibb, Princeton, NJ, USA.
17. Klein TE, Chang JT, Cho MK et al. Integrating genotype and phenotype information: an overview of the PharmGKb project. Pharmacogenetics research network and knowledge base. Pharmacogenomics J. 1(3), 167-170 (2001). (Pubitemid 33756654)
18. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9. *8 is prevalent among African- Americans: implications for pharmacogenetic dosing. Pharmacogenomics 10(8), 1243-1255 (2009).
19. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 11(6), 781-791 (2010).
20. Lima MV, Ribeiro GS, Mesquita ET, Victer PR, Vianna-Jorge R. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur. J. Clin. Pharmacol. 64(1), 9-15 (2008).
21. Adcock DM, Koftan C, Crisan D, Kiechle FL. Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation. Arch. Pathol. Lab. Med. 128(12), 1360-1363 (2004). (Pubitemid 39627472)
22. Herman D, Locatelli I, Grabnar I et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 5(3), 193-202 (2005). (Pubitemid 40852221)
23. Redman AR, Zheng J, Shamsi SA et al. Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy. Clin. Appl. Thromb. Hemost. 14(1), 29-37 (2008).
24. Anderson JL, Horne BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563-2570 (2007). (Pubitemid 350179221)
25. Lenzini P, Wadelius M, Kimmel S et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin. Pharmacol. Ther. 87(5), 572-578 (2010).
26. Linder MW, Bon Homme M, Reynolds KK et al. Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. Clin. Chem. 55(10), 1861-1868 (2009).
27. McMillin GA, Melis R, Wilson A et al. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. Ther. Drug Monit. 32(3), 338-345 (2010).
28. Sasaki T, Tabuchi H, Higuchi S, Ieiri I. Warfarin-dosing algorithm based on a population pharmacokinetic/ pharmacodynamic model combined with Bayesian forecasting. Pharmacogenomics 10(8), 1257-1266 (2009).
29. Bodin L, Horellou MH, Flaujac C, Loriot MA, Samama MM. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J. Thromb. Haemost. 3(7), 1533-1535 (2005). (Pubitemid 41725215)
30. Geisen C, Watzka M, Sittinger K et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost. 94(4), 773-779 (2005). (Pubitemid 41489236)
31. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 427(6974), 541-544 (2004). (Pubitemid 38209111)
32. Loebstein R, Dvoskin I, Halkin H et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109(6), 2477-2480 (2007). (Pubitemid 46425891)
33. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005). (Pubitemid 40740552)
34. Rost S, Fregin A, Ivaskevicius V et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974), 537-541 (2004). (Pubitemid 38209110)
35. Yuan HY, Chen JJ, Lee MT et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14(13), 1745-1751 (2005). (Pubitemid 41430097)
36. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112(4), 1013-1021 (2008).
37. Caldwell MD, Berg RL, Zhang KQ et al. Evaluation of genetic factors for warfarin dose prediction. Clin. Med. Res. 5(1), 8-16 (2007). (Pubitemid 350218774)
38. Carlquist JF, Horne BD, Mower C et al. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J. Thromb. Thrombolysis 30(3), 358-364 (2010).
39. D'Ambrosio RL, D'Andrea G, Cappucci F et al. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica 89(12), 1510-1516 (2004).
40. Uno T, Sugimoto K, Sugawara K, Tateishi T. The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers. J. Clin. Pharm. Ther. 33(1), 67-73 (2008).
41. Cooper GM, Johnson JA, Langaee TY et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112(4), 1022-1027 (2008).
42. Takeuchi F, McGinnis R, Bourgeois S et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), e1000433 (2009).
43. Caldwell MD, Awad T, Johnson JA et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111(8), 4106-4112 (2008).
44. Zhang JE, Jorgensen AL, Alfirevic A et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet. Genomics 19(10), 781-789 (2009).
45. McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol. 75(6), 1337-1346 (2009).
46. Perez-Andreu V, Roldan V, Anton AI et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 113(20), 4977-4979 (2009).
47. Stec DE, Roman RJ, Flasch A, Rieder MJ. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol. Genomics 30(1), 74-81 (2007). (Pubitemid 47173292)
48. Hsu MH, Savas U, Griffin KJ, Johnson EF. Regulation of human cytochrome P450 4F2 expression by sterol regulatory element-binding protein and lovastatin. J. Biol. Chem. 282(8), 5225-5236 (2007). (Pubitemid 47093716)
49. Sconce EA, Khan TI, Wynne HA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7), 2329-2333 (2005). (Pubitemid 41510803)
50. Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
51. Klein TE, Altman RB, Eriksson N et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
52. Roper N, Storer B, Bona R, Fang M. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J. Mol. Diagn. 12(3), 283-291 (2010).
53. Rahman M, BinEsmael TM, Payne N, Butchart EG. Increased sensitivity to warfarin after heart valve replacement. Ann. Pharmacother. 40(3), 397-401 (2006).
54. King CR, Porche-Sorbet RM, Gage BF et al. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am. J. Clin. Pathol. 129(6), 876-883 (2008).
55. Lyon E, McMillin G, Melis R. Pharmacogenetic testing for warfarin sensitivity. In:Clinics in Laboratory Medicine: Pharmacogenetics . Reynolds KK, Valdes R, Wells A (Eds).WB Saunders Company, PA, USA, 525-537 (2009).
56. Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).J. Am. Coll. Cardiol. 55(25), 2804-2812 (2010).
57. Lenzini PA, Grice GR, Milligan PE et al. Optimal initial dose adjustment of warfarin in orthopedic patients. Ann. Pharmacother. 41(11), 1798-1804 (2007). (Pubitemid 350044341)
58. Millican EA, Lenzini PA, Milligan PE et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110(5), 1511-1515 (2007). (Pubitemid 47443966)
59. Cushman M, Booth SL, Possidente CJ, Davidson KW, Sadowski JA, Bovill EG. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br. J. Haematol. 112(3), 572-577 (2001). (Pubitemid 32222825)
60. Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb. Haemost. 93(5), 872-875 (2005). (Pubitemid 40691544)
61. Sorano GG, Biondi G, Conti M, Mameli G, Licheri D, Marongiu F. Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal. Haemostasis 23(2), 77-82 (1993). (Pubitemid 23251029)
62. Schurgers LJ, Shearer MJ, Hamulyak K, Stocklin E, Vermeer C. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood 104(9), 2682-2689 (2004). (Pubitemid 39434948)
63. Reese AM, Farnett LE, Lyons RM, Patel B, Morgan L, Bussey HI. Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy 25(12), 1746-1751 (2005). (Pubitemid 41790098)
64. Ford SK, Misita CP, Shilliday BB, Malone RM, Moore CG, Moll S. Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios. J. Thromb. Thrombolysis 24(1), 23-27 (2007). (Pubitemid 46831560)
65. Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 109(6), 2419-2423 (2007). (Pubitemid 46425883)
66. Rombouts EK, Rosendaal FR, Van Der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J. Thromb. Haemost. 5(10), 2043-2048 (2007). (Pubitemid 47450022)
67. Garcia-Alamino JM, Ward AM, Alonso-Coello P et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst. Rev. (4), CD003839 (2010).
68. Matchar DB, Jacobson A, Dolor R et al. Effect of home testing of international normalized ratio on clinical events. N. Engl. J. Med. 363, 1608-1620 (2010).
69. Cromheecke ME, Levi M, Colly LP et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 356(9224), 97-102 (2000). (Pubitemid 30438510)
70. Gadisseur AP, Kaptein AA, Breukink-Engbers WG, van der Meer FJ, Rosendaal FR. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. J. Thromb. Haemost. 2(4), 584-591 (2004). (Pubitemid 40185681)
71. Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self- Management of Oral Anticoagulation. JAMA 281(2), 145-150 (1999). (Pubitemid 29045346)
72. Ryan F, Byrne S, O'shea S. Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. J. Thromb. Haemost. 7(8), 1284-1290 (2009).
73. Kong MC, Lim TG, Ng HJ, Chan YH, Lee LH. Feasibility, cost-effectiveness and patients' acceptance of point-of-care INR testing in a hospital-based anticoagulation clinic. Ann. Hematol. 87(11), 905-910 (2008).
74. Laurence CO, Moss JR, Briggs NE, Beilby JJ. The cost-effectiveness of point of care testing in a general practice setting: results from a randomized controlled trial. BMC Health Serv. Res. 10, 165 (2010).
75. Regier DA, Sunderji R, Lynd LD, Gin K, Marra CA. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ 174(13), 1847-1852 (2006). (Pubitemid 43974090)
76. White HD, Gruber M, Feyzi J et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch. Intern. Med. 167, 239-245 (2007)
77. Pradaxa® (dabigatran etexilate mesylate), package insert. Boehringer Ingleheim Pharmaceuticals Corp., Ridgefield, CT, USA.
78. Connolly SJ, Ezekowitz MD, Phil D et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139-1151 (2009).
79. Wallentin L, Yusuf S, Ezekowitz MD et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376, 975-983 (2010).
80. Pendleton RC, Rodgers GM, Hull RD. Established venous thromboembolism therapies: heparin, low molecular weight heparins, and vitamin k antagonists, with a discussion of heparin-induced thrombocytopenia. Clin. Chest Med. 31(4), 691-706 (2010).